A useful biomarker starts with a clearly defined clinical question
LinkedIn caption
📊 A useful biomarker starts with a clearly defined clinical question
At ARDD 2026, Steven Quay of Atossa Therapeutics described a development strategy that first specifies the indication, population and condition, then selects an appropriate surrogate endpoint. The official recap highlights mammographic breast density as an example being developed for breast cancer prevention through an accelerated-approval approach, with clinical outcomes to be confirmed later.
💡 For aging-related therapies, the broader lesson is practical: a biomarker needs a defined role in the trial and a credible connection to outcomes that matter to patients.
#ARDD2026 #ClinicalTrials
X caption
📊 At #ARDD2026, Steven Quay connected biomarker strategy with a defined indication and patient population, using breast density as a proposed surrogate for breast cancer prevention. Clinical outcomes still need to be confirmed as the strategy develops.
#ClinicalTrials
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
